Ullman Cited in Article on FDA’s Takedown of NMN
November 15, 2022 | |Marc Ullman was cited in the NutraIngredientsUSA article, “FDA’s takedown of NMN raises fairness transparency concerns.”
The FDA has disallowed the anti-aging ingredient, NMN, and this has raised questions of fairness and transparency.
Ullman said the current FDA interpretation sets up a situation in which a pharma company could file an IND, let the issue lie fallow, and then reinvigorate its drug development after a supplemental company has developed new applications for the same substance.
“This interpretation will have a chilling effect on the development of new products to support public health,” stated Ullman.
Read the full article here.
